1. Home
  2. IAUX vs TSHA Comparison

IAUX vs TSHA Comparison

Compare IAUX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.76

Market Cap

1.5B

Sector

N/A

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.74

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IAUX
TSHA
Founded
2020
2019
Country
United States
United States
Employees
133
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
IAUX
TSHA
Price
$1.76
$4.74
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$1.50
★ $11.63
AVG Volume (30 Days)
★ 8.0M
2.6M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 11.76
5.56
EPS
★ N/A
N/A
Revenue
★ $95,193,000.00
$9,773,000.00
Revenue This Year
$132.25
N/A
Revenue Next Year
$89.76
$1,152.42
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 89.12
17.28
52 Week Low
$0.89
$3.10
52 Week High
$2.24
$7.30

Technical Indicators

Market Signals
Indicator
IAUX
TSHA
Relative Strength Index (RSI) 51.81 30.23
Support Level $1.59 $4.37
Resistance Level $1.95 $5.07
Average True Range (ATR) 0.07 0.23
MACD -0.01 -0.03
Stochastic Oscillator 51.92 8.15

Price Performance

Historical Comparison
IAUX
TSHA

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: